Company Overview - Phreesia is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care[8] - The company operates a SaaS platform to manage patient intake and offers an integrated patient payments solution[8] - Phreesia processed $1.4 billion in patient payments in FY19[8] - The company serves approximately 1,600 healthcare provider organizations[8, 22] Financial Performance and Market Opportunity - Phreesia's revenue in FY19 was $100 million, demonstrating over 25% growth[8, 9] - The company estimates a total addressable market (TAM) of approximately $7 billion[9] - Subscription and related services accounted for 44% of FY19 revenue, while payment processing contributed 37%, and life sciences 19%[34] - In Q2 2020, total revenue reached $30.8 million, a 24.4% increase compared to Q2 2019[42] Growth Strategy - Phreesia aims to land new clients, grow its footprint within existing clients, and cross-sell new applications[27] - The company focuses on margin expansion through scale and strategic partnerships and M&A[27] - Phreesia achieved a 107% dollar-based net retention rate in FY19[27]

Company Overview - eXp World Holdings operates as a global cloud-based real estate brokerage and enterprise metaverse platform[5] - The company has a global network of over 80,000 agents as of April 20, 2022[9, 10] - eXp's revenues (TTM) are $42 billion as of March 31, 2022[11] Financial Performance - Q1 2022 revenue was over $427 million, with net income exceeding $4 million compared to 2021[9] - The company has consistent positive cash flow and no long-term debt[9] - Total Q1 2022 revenue reached $1 billion[16] Growth and Competitive Advantage - eXp Realty is ranked as the 1 growth leader across agent count, volume, and transactions[9, 10, 20] - The company experienced 55% year-over-year agent growth in Q1 2022[16] - eXp is capturing global market share with 314%+ year-over-year international agent growth[23] Agent Value Proposition - eXp offers a unique agent value proposition, including an attractive commission structure, revenue share, and equity[7] - Agents receive an 80/20 commission split with a $16,000 cap[27, 55] - The company provides equity awards for agents meeting production criteria[21, 27]

Company Overview - eXp World Holdings operates a global cloud-based real estate brokerage and enterprise metaverse platform[5] - The company also has an ecosystem of personal development resources and media[6] - eXp's cloud-based model enables richer unit economics and broader geographical reach for agents[20] Financial Performance - eXp World Holdings' Q2 2022 revenue increased by 42% year-over-year[11] - The company's operating cash flow increased by 27% year-over-year[11] - As of June 30, 2022, eXp World Holdings had $134.9 million in cash and cash equivalents[13] - The company's total revenue for the trailing twelve months (TTM) ending Q2 2022 was $46132 million[16] Agent Growth and Global Expansion - eXp has over 83000 agents as of August 3, 2022[11] - Agent growth in Q2 2022 was 42% year-over-year[18] - eXp is expanding globally with 21 markets worldwide[11] - The company experienced 94% year-over-year international agent growth[25] Agent Value Proposition - eXp returns over 90% of commission to agents, inclusive of revenue share and equity[24] - Agents receive an 80/20 split on first $80000 gross commission income (GCI) with a $16000 yearly cap[30]

Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other major marketsMedicinal product classification supports unified global regulatory classification, facilitating future global strategies and filingsNew composition of matter patent for JNJ-1900 (NBTXR3) filed by Nanobitotix PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO ...

They're literally telegraphing infinite money printer all day every day and you're still barely allocated to the only assets that can possibly survive a total debasement of the currencyok (BTC to infinity)zerohedge (@zerohedge):Fed Study Finds 9% Chance of Rates Hitting Zero in Medium Term(narrator: rates will hit zero in the medium term, guaranteed) ...

"To beat BTC, companies must do more than just buy and hold it. They must figure out how to build a Bitcoin-based business," says @TorbjrnBullJens @K33HQ.Opinion.https://t.co/eAMGptaGfX ...

Core Viewpoint - Intellia Therapeutics (NTLA) has demonstrated significant stock performance, with a 29.8% increase over the past month, outperforming the industry and the S&P 500 index [1][7]. Company Performance - The company's stock performance is attributed to advancements in its pipeline development and increased interest in gene therapies following Eli Lilly's acquisition of Verve Therapeutics [3][4]. - Intellia is transitioning towards becoming a commercial-ready organization by the end of 2026 [9]. Pipeline Development - Intellia is advancing two late-stage in vivo candidates: nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) [4][8]. - Nex-z is currently undergoing two phase III studies, with enrollment in the MAGNITUDE 2 study expected to complete by 2026 and a potential biologics license application planned for 2028 [5][6]. - Lonvo-z is in the pivotal phase III HAELO study, with enrollment expected to complete by Q3 2025 and a regulatory filing planned for the second half of 2026 [8]. Competitive Landscape - Intellia faces competition from other companies utilizing CRISPR/Cas9 technology, such as CRISPR Therapeutics, which recently received approval for its gene-edited therapy, Casgevy [12][13]. - The company has decided to halt the development of its in vivo gene insertion candidate, NTLA-3001, and plans to reduce its workforce by nearly 27% in 2025 [13]. Financial Outlook - NTLA shares currently trade at a price/book ratio of 1.43, below the industry average of 3.13 [14]. - The Zacks Consensus Estimate for NTLA's loss per share has narrowed for both 2025 and 2026, indicating a potential improvement in financial performance [16]. Conclusion - Intellia's recent stock rally is promising, but the lack of an approved product remains a significant challenge [17]. - The successful development of its pipeline candidates is crucial for the company's future [17][18].

Core Viewpoint - Johnson & Johnson's MedTech segment, which constitutes approximately 36% of total revenues, is experiencing growth driven by newly acquired cardiovascular businesses and new product uptake, but faces challenges in the Asia Pacific region, particularly in China due to government procurement programs and competitive pressures [1][2][4]. Group 1: MedTech Segment Performance - The MedTech segment's growth in Q2 is attributed to the acquisition of Abiomed and Shockwave, alongside the continued uptake of new products [2]. - Sales in China are negatively impacted by the volume-based procurement (VBP) program and an anticorruption campaign, with no expected improvement in 2025 [2]. - Competitive pressures are affecting growth in specific MedTech areas, such as PFA ablation catheters in U.S. electrophysiology [3]. Group 2: Future Outlook - Sales are anticipated to be higher in the second half of 2025 compared to the first half as the business overcomes challenging first-quarter comparisons and new products gain traction [4]. - Tariff-related costs are expected to negatively impact profits in the MedTech segment [4]. Group 3: Competitive Landscape - J&J's MedTech unit faces significant competition from major players like Medtronic, Abbott, Stryker, and Boston Scientific, each specializing in various medical technologies [4][5]. Group 4: Financial Performance and Valuation - J&J's shares have outperformed the industry with a year-to-date increase of 9.7%, compared to a 0.6% rise in the industry [6]. - The company's shares are reasonably priced, trading at a price/earnings ratio of 14.43, lower than the industry average of 14.99 and below its five-year mean of 15.73 [8]. - The Zacks Consensus Estimate for 2025 earnings has increased slightly from $10.60 to $10.62 per share over the past 30 days [10].

Stablecoin monthly active users (MAUs) are at an all-time high of ~20 million.@revolut, the fintech with ~55 million retail customers, is rumored to be building its own stablecoin.Revolut alone could ~2x the onchain user base of stablecoins. https://t.co/8NPgf6xLRp ...

Chinese tech giant https://t.co/knkdFZ2Khz and @AntGroup are reportedly pushing the country's central bank to permit yuan-based stablecoins to counter the rise of U.S. dollar-linked digital currencies. By @JamieCrawleyCD.https://t.co/OEyHz2LMOR ...